Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 0009K01 approvals

Aimed Bio Inc.

Official website

KOSDAQ-listed ADC oncology biotech that has out-licensed pipeline candidates to Biohaven, SK Plasma, and Boehringer Ingelheim.

As of 2026-10-10, Aimed Bio Inc. has 1 Korean MFDS device approval, 7 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2018 and listed on KOSDAQ in 2025, Aimed Bio is an ADC (antibody-drug conjugate)-focused oncology biotech spun off from Samsung Medical Center. Leveraging antibody discovery capabilities based on patient-derived cells (PDC) and patient-derived xenograft (PDX) models along with its proprietary linker-payload technology, its pipeline includes the FGFR3-targeting ADC AMB302, the ROR1-targeting ADC AMB303, and the undisclosed-target ADC ODS025. It out-licensed AMB302 to Biohaven in December 2024, entered a co-development and license agreement for AMB303 with SK Plasma in May 2025, and out-licensed ODS025 to Boehringer Ingelheim in October 2025 for a total contract value of USD 991,000,000.

Regulatory approvals

data.go.kr

1 Korean MFDS device approvals · 2023

  • MFDSSpecimen transport media2023-02-08
    Product approval · Class 1체외 제신 23-171 호

R&D and key agreements

Source: DART corporate disclosure

AMB302 (FGFR3 표적 ADC) · 방광암·두경부암·뇌종양 등 FGFR3 과발현/변이 고형암 · 임상1상(미국) · First-in-class ADC combining a Topo1 inhibitor payload; US Phase 1 IND approved Sep 2024

AMB303 (ROR1 표적 ADC) · ROR1 과발현 고형암(폐암·유방암·난소암 등) 또는 혈액암 · IND enabling study · Co-developed and licensed with SK Plasma

ODS025 · 비공개 타겟 과발현 고형암 · IND enabling study · Out-licensed to Boehringer Ingelheim; total deal value USD 991,000,000

PP1, PP2 · 이중 타겟 과발현 고형암 · 연구개발 단계 · Bispecific antibody ADC candidates

Key disclosures

KRX KIND via OpenDART
Show 3 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 29 more patents

AI reads

MAA server logs · IP-verified
49
Times AI engines pulled Aimed Bio Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

3
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

46
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

7
live 1
Last 7 days
41
live 3
Last 30 days
49
live 3
All time
  • OpenAIChatGPT-Userlive3
  • OpenAIOAI-SearchBot36
  • GoogleGoogleOther4
  • PerplexityPerplexityBot3
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Aimed Bio Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · products. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Ensol Biosciences Inc.1 shared

Ensol Biosciences is a KONEX-listed biotech developing short peptide therapeutics that modulate protein-protein interactions (PPI).

Synergy Innovation Co., Ltd.1 shared

Synergy Innovation, founded in 1998 and KOSDAQ-listed in 2004, manufactures and sells microbial culture media.

Gencurix Inc.1 shared

Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.

CJ Bioscience1 shared

CJ Bioscience develops microbiome drugs CJRB-101, CJRB-201 via AI platform Ez-Mx®, and runs gut-health services GUT INSIDE, SMILE GUT.

Xcell Therapeutics Inc.1 shared

Xcell Therapeutics develops the domestically produced CellCor™ cell culture media series for cell and gene therapy manufacturing.

PCL. Inc1 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

RollingStone Co., Ltd.1 shared

KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.

LabGenomics. Co., Ltd.1 shared

KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.

SEEGENE, INC.1 shared

Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.

BIODYNE CO., LTD.1 shared

Founded in 1999 and KOSDAQ-listed in 2021, BIODYNE develops liquid-based cytology (LBC) devices and diagnostic reagent kits.

VIVOZON PHARMACEUTICAL CO., LTD.1 shared

Vivozon Pharmaceutical, founded in 2002 and KOSDAQ-listed in 2005, makes ETC/OTC drugs and runs CMO/OEM businesses across about 190 items.

SD BIOSENSOR INC.1 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition